SCHEMBL13209359

SCHEMBL13209359

CC1CN(C(C)(C)C)c2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.50
ROCK1 Q13464 1/20 0.42
GPR3 P46089 1/20 0.39
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
TSHR P16473 1/20 0.35
ACHE P22303 2/20 0.34
GAA P10253 1/20 0.33
G6PD P11413 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SLC6A2 P23975 7/20 0.33
SLC6A4 P31645 7/20 0.33
OPRM1 P35372 1/20 0.33
OPRK1 P41145 1/20 0.33
OPRL1 P41146 1/20 0.33
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TP53 P04637 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13209367 0.81 NOTUM (0.40) NOTUMROCK1GPR3DRD2DRD4
SCHEMBL24663253 0.79 GPR3 (0.34) NOTUMGPR3DRD2DRD4TSHR
SCHEMBL3750926 0.78 NOTUM (0.44) NOTUMTSHRMEN1ALDH1A1KMT2A
SCHEMBL25121801 0.77 SLC6A2 (0.40) GPR3SLC6A2SLC6A4SLC6A3
SCHEMBL13209360 0.77 SLC6A2 (0.37) NOTUMGPR3DRD4ACHESLC6A2
SCHEMBL2625781 0.74 NOTUM (0.55) NOTUMROCK1GPR3DRD2DRD4
SCHEMBL18681421 0.74 NOTUM (0.55) NOTUMROCK1GPR3DRD2DRD4
SCHEMBL22240446 0.74 NOTUM (0.55) NOTUMROCK1GPR3DRD2DRD4
SCHEMBL13372442 0.74 NOTUM (0.55) NOTUMROCK1GPR3DRD2DRD4
SCHEMBL30305195 0.73 NOTUM (0.40) NOTUMKDM4EMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329718-B2 N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions BRISTOL-MYERS SQUIBB COMPANY (US) 2012-12-11 US disclosed
US-8329718-B2 N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions BRISTOL-MYERS SQUIBB COMPANY (US) 2012-12-11 US disclosed
US-20100197716-A1 N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2010-08-05 US disclosed
US-20100197716-A1 N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2010-08-05 US disclosed
US-7728008-B2 N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-01 US disclosed
US-7550499-B2 Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-23 US disclosed
US-7550499-B2 Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197716-A1 N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS P2RY1, P2RY11, P2RY13 NOTUM 4169/4885ROCK1 3215/4885GPR3 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.